As shown in preclinical studies, ISM6200 is a small molecule candidate with low DDI risk and higher in vivo efficacy across multiple animal models. (IMAGE)

InSilico Medicine

As shown in preclinical studies, ISM6200 is a small molecule candidate with low DDI risk and higher in vivo efficacy across multiple animal models.

Caption

In a preclinical CDX (cell line-derived xenograft) model, ISM6200 demonstrated significant and dose-dependent enhancement of anti-tumor efficacy when combined with paclitaxel. Also, a favorable ADME and pharmacokinetic profile support strong systemic exposure and a low predicted efficacious dose in humans, and its solid developability profile marked by good stability lays the foundation as a therapeutically effective agent.

Credit

Insilico Medicine

Usage Restrictions

None

License

Original content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.